hydroxyprogesterone caproate - direct healthcare professional communication (DHPC)

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Hydroxyprogesterone caproate (17-OHPC)-containing medicinal products : Suspension of the marketing authorisations of medicinal products containing hydroxyprogesterone caproate

Key facts

• Active substance:
  hydroxyprogesterone caproate
• Procedure number:
  EMEA-H-A-31-1528
• Regulatory outcome:
  Suspension
• DHPC type:
  Post-authorisation measure
• Referral name:
  Hydroxyprogesterone caproate-containing medicinal products
• Dissemination date:
  17/07/2024
• Related medicines:
  • Lentogest
  • Progesterone Retard Pharlon
  • Proluton Depot